SCHEMBL4957822

SCHEMBL4957822

Cc1ccc(C(=O)O)c(CN)c1B(O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 3/20 0.35
GABRD O14764 3/20 0.35
GABRA1 P14867 3/20 0.35
GABRB1 P18505 3/20 0.35
GABRG2 P18507 3/20 0.35
GABRB3 P28472 3/20 0.35
GABRA5 P31644 3/20 0.35
GABRA3 P34903 3/20 0.35
GABRA2 P47869 3/20 0.35
GABRB2 P47870 3/20 0.35
GABRA4 P48169 3/20 0.35
GABRE P78334 3/20 0.35
GABRA6 Q16445 3/20 0.35
GABRG1 Q8N1C3 3/20 0.35
GABRG3 Q99928 3/20 0.35
GABRQ Q9UN88 3/20 0.35
HAAO P46952 1/20 0.35
MYC P01106 2/20 0.34
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4937360 0.79 GABRP (0.39) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL28360290 0.75 CYP1A2 (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL27893912 0.72 GABRP (0.37) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2227278 0.72 ALDH1A1 (0.55) MYCKDM4EALDH1A1HPGDHSD17B10
SCHEMBL2064870 0.69 ALDH1A1 (0.57) MYCKDM4EALDH1A1HPGDHSD17B10
SCHEMBL600023 0.69 HMGB1 (0.41) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2382535 0.68 LOXL2 (0.40) KDM4EALDH1A1HPGDHSD17B10CD274
SCHEMBL27669069 0.68 HMGB1 (0.55) MYCKDM4EALDH1A1HPGDHSD17B10
SCHEMBL29850850 0.67 HAAO (0.41) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL28733643 0.67 GABRP (0.42) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7316999-B2 Glucose dependent release of insulin from glucose sensing insulin derivatives NOVO NORDISK A/S (DK) 2008-01-08 US disclosed
EP-1290024-A1 GLUCOSE DEPENDENT RELEASE OF INSULIN FROM GLUCOSE SENSING INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2003-03-12 EP disclosed
US-20020028767-A1 Glucose dependent release of insulin from glucose sensing insulin derivatives NOVO NORDISK A/S (DK) 2002-03-07 US disclosed
WO-2001092334-A1 GLUCOSE DEPENDENT RELEASE OF INSULIN FROM GLUCOSE SENSING INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028767-A1 Glucose dependent release of insulin from glucose sensing insulin derivatives GPR119, IRS1, IAPP GABRP 1450/4885GABRD 1861/4885GABRA1 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.